NEW YORK (AP) -- Keryx Biopharmaceuticals said Friday that it appointed Daniel P. Regan of Intercept Pharmaceuticals to its board of directors.
Regan, 49, will be the seventh member of Keryx's board. The company said Regan, 49, worked for Genzyme from 1999 to 2011 and was in charge of marketing the company's kidney disease drugs. He is currently the chief commercial officer for Intercept Pharmaceuticals Inc.
Keryx Biopharmaceuticals Inc. does not have any approved drugs. It is running clinical trials of Zerenex, a treatment for elevated phosphate levels in dialysis patients with chronic kidney disease.
Genzyme was acquired by French drugmaker Sanofi in April 2011.
Its shares rose 9 cents to $10.30 in morning trading Friday. Its shares hit a 52-week high of $10.92 on Wednesday.
- Health Care Industry